
US healthcare investment firm TCGX has closed its first Asia-focused life sciences fund at $600 million and is opening offices in Shanghai and Hong Kong to support investments in biotechnology companies across the region.
The privately held firm announced Wednesday that TCGX Asia Life Sciences Fund I was oversubscribed and backed by international institutional investors. It did not identify those investors or disclose individual commitments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze